Skip to main content
Year archive

Compugen Ltd. — 2022 filings

All 84 regulatory filings released by Compugen Ltd. (CGEN) in 2022, sourced directly from the official regulator.

84 Filings
2022 Period
2022 filings (84)
Filing Released Lang
Compugen’s COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer
Regulatory Filings
2022-12-06 English
Compugen’s COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer
Report Publication Announcement
2022-12-06 English
Bayer notified the “Company that it has resolved to terminate, effective as of February 27, 2023, the parties’ research and development collaboration and license agreement, previously effective as of
Regulatory Filings
2022-12-02 English
Bayer notified the “Company that it has resolved to terminate, effective as of February 27, 2023, the parties’ research and development collaboration and license agreement, previously effective as of
Report Publication Announcement
2022-12-02 English
COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patient
Regulatory Filings
2022-12-01 English
COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patient
Report Publication Announcement
2022-12-01 English
Compugen to Participate in the JMP Securities Hematology and Oncology Summit
Regulatory Filings
2022-11-29 English
Compugen to Participate in the JMP Securities Hematology and Oncology Summit
Report Publication Announcement
2022-11-29 English
Compugen to Receive Milestone Payment Triggered by AstraZeneca’s Phase 2 Initiation of PD-1/TIGIT Bispecific
Regulatory Filings
2022-11-16 English
Compugen to Receive Milestone Payment Triggered by AstraZeneca’s Phase 2 Initiation of PD-1/TIGIT Bispecific
Report Publication Announcement
2022-11-16 English
6K: Third Quarter 2022 Results
Interim / Quarterly Report Q3 2022
2022-11-14 English
6K: Third Quarter 2022 Results
Report Publication Announcement
2022-11-14 English
Compugen to Participate in the Stifel Healthcare Conference
Regulatory Filings
2022-11-08 English
Compugen to Participate in the Stifel Healthcare Conference
Report Publication Announcement
2022-11-08 English
publication of the abstract on data demonstrating that anti-tumor activity following blockade of PVRIG with COM701 is supported by potent tumor microenvironment (TME) immune activation in MSS-CRC pati
Regulatory Filings
2022-11-07 English
publication of the abstract on data demonstrating that anti-tumor activity following blockade of PVRIG with COM701 is supported by potent tumor microenvironment (TME) immune activation in MSS-CRC pati
Report Publication Announcement
2022-11-07 English
Compugen Announces Receipt of Nasdaq Delisting Notice
Delisting Announcement
2022-11-02 English
Compugen Announces Receipt of Nasdaq Delisting Notice
Report Publication Announcement
2022-11-02 English
Compugen to Release Third Quarter 2022 Results on Monday, November 14, 2022
Report Publication Announcement
2022-10-31 English
Compugen to Release Third Quarter 2022 Results on Monday, November 14, 2022
Report Publication Announcement
2022-10-31 English
Compugen to Present New Clinical Data at ESMO-IO
Regulatory Filings
2022-10-26 English
Compugen to Present New Clinical Data at ESMO-IO
Report Publication Announcement
2022-10-26 English
Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022
Investor Presentation
2022-10-06 English
Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022
Report Publication Announcement
2022-10-06 English
Letter to Shareholders
Regulatory Filings Q2 2022
2022-09-22 English
Letter to Shareholders
Report Publication Announcement
2022-09-22 English
6K: On September 14, 2022 the “Company held its 2022 Annual General Meeting of Shareholders
Regulatory Filings
2022-09-15 English
6K: On September 14, 2022 the “Company held its 2022 Annual General Meeting of Shareholders
Report Publication Announcement
2022-09-15 English
Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer
Board/Management Information
2022-09-12 English
Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer
Report Publication Announcement
2022-09-12 English
Compugen to Participate in Upcoming Fierce Biotech Summit
Regulatory Filings
2022-09-07 English
Compugen to Participate in Upcoming Fierce Biotech Summit
Report Publication Announcement
2022-09-07 English
Compugen Expands anti-PVRIG COM701 Patent Portfolio with New Composition of Matter and Use Patent in Japan
Regulatory Filings
2022-08-24 English
Compugen Expands anti-PVRIG COM701 Patent Portfolio with New Composition of Matter and Use Patent in Japan
Report Publication Announcement
2022-08-24 English
Compugen Expands anti-PVRIG COM701 Intellectual Property Portfolio
Regulatory Filings
2022-08-08 English
Compugen Expands anti-PVRIG COM701 Intellectual Property Portfolio
Report Publication Announcement
2022-08-08 English
FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
Capital/Financing Update
2022-08-04 English
FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
Regulatory Filings
2022-08-04 English
Annual General Meeting of Shareholders to be held on Wednesday, September 14, 2022
AGM Information
2022-08-04 English
Annual General Meeting of Shareholders to be held on Wednesday, September 14, 2022
AGM Information
2022-08-04 English
Mr. Krashin, pursuant to which he will provide CFO operating Officer services to support the Company until a successor joins the Company
Board/Management Information
2022-08-04 English
Mr. Krashin, pursuant to which he will provide CFO operating Officer services to support the Company until a successor joins the Company
Report Publication Announcement
2022-08-04 English
Termination of the Master Clinical Trial Collaboration Agreement between Compugen and BMS
Regulatory Filings
2022-08-04 English
Termination of the Master Clinical Trial Collaboration Agreement between Compugen and BMS
Report Publication Announcement
2022-08-04 English
K-6- Reports Second Quarter 2022 Results
Interim / Quarterly Report Q2 2022
2022-08-04 English
K-6- Reports Second Quarter 2022 Results
Report Publication Announcement
2022-08-04 English
ompugen to Release Second Quarter Results on Thursday, August 4, 2022
Report Publication Announcement
2022-07-21 English
ompugen to Release Second Quarter Results on Thursday, August 4, 2022
Report Publication Announcement
2022-07-21 English
to Present at Upcoming Industry Conferences
Regulatory Filings
2022-06-27 English
to Present at Upcoming Industry Conferences
Report Publication Announcement
2022-06-27 English
Compugen to Present at Upcoming Investor Conferences
Regulatory Filings
2022-06-01 English
Compugen to Present at Upcoming Investor Conferences
Report Publication Announcement
2022-06-01 English
Reports First Quarter 2022 Results
Interim / Quarterly Report Q1 2022
2022-05-16 English
Reports First Quarter 2022 Results
Report Publication Announcement
2022-05-16 English
Mr. Ari Krashin, Chief Financial Officer and Chief Operating Officer notified the Company of his wish to depart from his position at the Company
Regulatory Filings
2022-05-10 English
Mr. Ari Krashin, Chief Financial Officer and Chief Operating Officer notified the Company of his wish to depart from his position at the Company
Report Publication Announcement
2022-05-10 English
first quarter 2022 financial results on Monday, May 16, 2022
Report Publication Announcement
2022-05-02 English
first quarter 2022 financial results on Monday, May 16, 2022
Report Publication Announcement
2022-05-02 English
Compugen’s Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of the Tumor Microenvironment
Regulatory Filings
2022-03-21 English
Compugen’s Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of the Tumor Microenvironment
Report Publication Announcement
2022-03-21 English
Compugen To Present New Insights into the Tumor Microenvironment Using Single Cell Spatial Transcriptomics at Keystone Symposium
Investor Presentation
2022-03-14 English
Compugen To Present New Insights into the Tumor Microenvironment Using Single Cell Spatial Transcriptomics at Keystone Symposium
Report Publication Announcement
2022-03-14 English
Compugen to Present at the Oppenheimer 32nd Annual Global Healthcare Conference
Report Publication Announcement
2022-03-09 English
Compugen to Present at the Oppenheimer 32nd Annual Global Healthcare Conference
Report Publication Announcement
2022-03-09 English
Compugen Presents New Research Suggesting Targeting DNAM-1 Axis Holds Promise for Treatment of Multiple Myeloma
Regulatory Filings
2022-03-09 English
Compugen Presents New Research Suggesting Targeting DNAM-1 Axis Holds Promise for Treatment of Multiple Myeloma
Report Publication Announcement
2022-03-09 English
FORM 20-F/A Amendment No. 1
Annual Report FY 2021
2022-03-01 English
FORM 20-F/A Amendment No. 1
Report Publication Announcement
2022-03-01 English
Form 20-F for 2021
Annual Report FY 2021
2022-02-28 English
Form 20-F for 2021
Report Publication Announcement
2022-02-28 English
Reports Fourth Quarter and Full Year 2021 Results
Earnings Release Q4 2021
2022-02-24 English
Reports Fourth Quarter and Full Year 2021 Results
Report Publication Announcement
2022-02-24 English
Schedule 13G/A filed by Nikko Asset Management Americas, Inc.
Major Shareholding Notification
2022-02-14 English
Schedule 13G/A filed by Nikko Asset Management Americas, Inc.
Major Shareholding Notification
2022-02-14 English
Compugen to Release Fourth Quarter and Full Year 2021 Results on Thursday, February 24, 2022
Report Publication Announcement
2022-02-10 English
Compugen to Release Fourth Quarter and Full Year 2021 Results on Thursday, February 24, 2022
Report Publication Announcement
2022-02-10 English
Schedule 13G/A filed by ARK Investment Management LLC
Major Shareholding Notification
2022-02-10 English
Schedule 13G/A filed by ARK Investment Management LLC
Regulatory Filings
2022-02-10 English
to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Regulatory Filings
2022-02-09 English
to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Report Publication Announcement
2022-02-09 English
SCHEDULE 13G/A-Nikko Asset Management
Major Shareholding Notification
2022-02-06 English
SCHEDULE 13G/A-Nikko Asset Management
Regulatory Filings
2022-02-06 English
Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with anti-PD-1 and anti-TIGIT Antibodies
Regulatory Filings
2022-01-18 English
Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with anti-PD-1 and anti-TIGIT Antibodies
Report Publication Announcement
2022-01-18 English